Your blood vessels have tiny channels that allow calcium to enter the muscle cells lining their walls. When calcium enters, it causes these vessels to squeeze and narrow, which drives up your blood pressure. Amlodipine acts like a plug in these channels, specifically blocking calcium from entering vascular smooth muscle. This forces the blood vessels to relax and widen, lowering your blood pressure and making it much easier for your heart to pump blood around the body.
Developed at Pfizer's research facility in Sandwich, Kent, as part of a systematic rational-design effort to overcome the pharmacokinetic limitations of early dihydropyridines like nifedipine. The objective was to create a calcium channel blocker with a very slow onset of action to prevent reflex tachycardia, combined with a half-life long enough to allow reliable once-daily dosing.
The dihydropyridine class of calcium channel blockers transformed hypertension management in the 1970s, but the first-generation agent, nifedipine, was heavily flawed. Its rapid onset and short duration caused abrupt vasodilation and reflex tachycardia, necessitating multiple daily doses and causing intolerable flushing. In the early 1980s, Pfizer scientists Simon Campbell and David Roberts systematically modified the dihydropyridine core to solve this. By attaching a basic aminoethoxy side chain, they created amlodipine (initially coded UK-48340) in 1982. This simple structural tweak drastically altered the drug's physical chemistry, turning it into a positively charged molecule at physiological pH that binds tightly to lipid cell membranes. This membrane-partitioning effect acts as a built-in slow-release mechanism, granting amlodipine a half-life approaching 50 hours. FDA approval followed in 1992 under the brand name Norvasc. It rapidly became the most prescribed antihypertensive globally, cementing its clinical dominance through landmark trials like ALLHAT, which proved its long-term cardiovascular mortality benefits matched or exceeded older, established classes.
Developed simultaneously for both essential hypertension and chronic stable angina, maintaining both as its dual primary indications from its initial approval.